Ascletis and Alphamab sign licensing deal for anti-PD-L1 to treat hepatitis B and other viral diseases
KN035 is an investigational programmed cell death ligand-1 (PD-L1) monoclonal antibody which has been exposed to more than 500 patients in multiple clinical trials in US, China and